Navigation Links
GSK and Adolor Announce Preliminary Results from Phase 3 Safety,Study of Alvimopan (Entereg/Entrareg)

in pain management, along with ingenuity, Adolor is seeking to make a positive difference for patients, caregivers and the medical community. For more information, visit www.adolor.com.

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit GlaxoSmithKline on the World Wide Web at www.gsk.com.

Adolor Forward-Looking Statements

This release, and oral statements made with respect to information contained in this release, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Such known risks and uncertainties relate to, among other factors: the risk that the OBD development program remains on hold indefinitely; the risk that Adolor may not receive regulatory approval of Entereg (R) (alvimopan) for POI, OBD, or any other indication; the risk that Adolor may not be able to adequately address the deficiencies in the November 2006 FDA approvable letter; the risk that a risk management plan could materially adversely affect the commercial prospects for Entereg, if regulatory approval is achieved; the risk that Adolor may not obtain FDA approval for Entereg in POI, whether due to Adolor's inability to provide additional data satisfactory to the FDA to obtain approval for the NDA, the adequacy of the safety and efficacy data from all of the
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/24/2014)... 24, 2014 Many new dentists who are opening ... ensure that their practice will be a success. DentalDisposables.net is ... they use the most can make all the difference. Dentistry ... recently discovered that purchasing discount dental supplies can ... According to successful dentists across the United States ...
(Date:7/24/2014)... 2014  Kinex Pharmaceuticals announced the receipt of an ... Ointment for the commencement of a Phase I clinical ... IND to be allowed by the US FDA in ... synthetic, orally active and highly selective inhibitor of Src ... induction of p53, G2/M arrest of proliferating cell populations ...
(Date:7/24/2014)... 24, 2014 Research and Markets  has ... Market by Product, Component, Application and Geography - Global ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... to witness a moderate growth as the markets of ... almost reached the saturation levels. The demand is expected ...
Breaking Medicine Technology:Dental Supplies Online is Key to Dental Success...Really! 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2
... College of Emergency Physicians 2009 Scientific Assembly ... medical device company developing innovative portable and ... launch of its new palm-sized, affordable ultrasound ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20091005/SF86741-a ) , (Logo: ...
... 5 Bausch & Lomb, the global eye health ... of Tubilux Pharma S.p.A. , Tubilux is a privately ... range of proprietary, over-the-counter, and branded generic products primarily ... countries. , Under the terms of the agreement, Bausch ...
Cached Medicine Technology:Signostics Introduces the World's Smallest Ultrasound Product for Global Demands of Affordable Healthcare 2Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux 2
(Date:7/24/2014)... 24, 2014 Members of the Iowa State ... CCIM, Senior Associate of Sales at OutcomesMTM, as their Chairperson. ... to the Board and that his peers chose to keep ... provide the best I can for the citizens of Iowa,” ... positioned to provide a special insight to concerns and issues ...
(Date:7/24/2014)... new study has shown that it is possible to predict ... short-term effects of that same exposure. The findings, which currently ... it possible to develop simpler and cheaper tests to screen ... Despite an overall decrease in incidence of and mortality from ... the disease in their lifetime, and around 20 percent will ...
(Date:7/24/2014)... rare procedure occasionally performed during Jewish circumcisions that involves ... herpes simplex virus type 1 (HSV-1) transmissions documented in ... conducted by Penn Medicine researchers and published online ... Society found. The reviewers, from Penn,s ... in New York, Canada and Israel. , The practiceknown ...
(Date:7/24/2014)... Human Papillomavirus Vaccination (HPV) even after becoming sexually ... results than those who were never vaccinated. These ... Diseases . , Researchers from Boston University ... conducted a cross-sectional study of 235 women age ... HPV status and demographic and behavioral characteristics were ...
(Date:7/24/2014)... July 24, 2014 According to ... Business Models, Technology Roadmap, Forecasts and Analysis - ... is expected to reach $7.7 billion by 2018 ... , Browse 102 market data tables and 30 ... on “3D Mapping Market: Global Advancements, Business Models, ...
Breaking Medicine News(10 mins):Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2Health News:Researchers discover new way to determine cancer risk of chemicals 2Health News:Link between ritual circumcision procedure and herpes infection in infants examined 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 2Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 3Health News:3D Mapping & 3D Modeling Market Projected to $7.7 Billion by 2018 - Report by MarketsandMarkets 4
... , , Congressman Chaka Fattah (D-PA) ... America,s healthcare system. , , WASHINGTON, Aug. 17 ... If real reform is to take place it must include a public ... airport in any major city they deliberate how they will get to their ...
... , , CHESTERFIELD, ... RELV ), a nutrition and direct selling company, today launched ... company,s line of proprietary nutritional supplements. , , ... Reliv,s breakthrough r(TM) skincare collection that combines some of the ...
... , , SAN FRANCISCO, ... leader in healthcare data management and decision support solutions ... a strategic alliance with CACTUS Software, a leading provider ... expand the capabilities and simplify the ability of healthcare ...
... , CHICAGO, Aug. 17 Presidential ... furnished two bedroom apartment to the University of Illinois Medical Center ... undergoing care at the medical center. , , ... Towers felt that this was a great way to give back ...
... PARK, N.J., Aug. 17 Managed Health Care Associates, Inc. ... joined MHA as Vice President & General Counsel. In ... all legal matters for the company, including healthcare compliance, contract ... and CFO of MHA commented "The establishment of this important ...
... Volumizing the Brow ... ... eyes change in generally predictable ways: the skin thins and becomes less elastic, brows may ... more prominent. While surgery has long been the accepted standard and offers significant benefits ...
Cached Medicine News:Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 2Health News:Reliv International Launches Relivables(TM) Product Family With New Skincare Products and Other Items 3Health News:Quantros and CACTUS Software Establish Strategic Alliance to Provide Customers With Comprehensive Provider Performance Monitoring 2Health News:Quantros and CACTUS Software Establish Strategic Alliance to Provide Customers With Comprehensive Provider Performance Monitoring 3Health News:Presidential Towers Donates Apartment to the University of Illinois Medical Center 2Health News:MHA Announces Gloria Barr, Esq. as Vice President & General Counsel 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 2Health News:Nonsurgical Technique Can Take Years Off the Appearance of Aging Eyes 3
... ESR-10 Manual Rack is a manual ... the erythrocyte sedimentation rate (ESR) of ... 1.2ml Streck ESR-Vacuum Tubes. The rack ... simultaneously. The ESR-10 Manual Rack exhibits ...
... assayed control for immunophenotyping with Beckman Coulter® ... the accuracy and reproducibility of all the ... including red blood cell lysis. Reference values ... lymphocytes, B lymphocytes, granulocytes, monocytes, and NK ...
... storage and transport solution formulated ... cells in samples without reducing ... Samples treated with Cyto-Chex can ... seven days prior to analysis ...
... specially designed for use with Coulter® ... package includes diluent, lysing agent, cleaning ... The 15L package configuration includes diluent, ... card. The shelf life is one ...
Medicine Products: